MicroRNA Expression Differentiates Squamous Epithelium from Barrett's Esophagus and Esophageal Cancer
Overview
Authors
Affiliations
Background: Current strategies fail to identify most patients with esophageal adenocarcinoma (EAC) before the disease becomes advanced and incurable. Given the dismal prognosis associated with EAC, improvements in detection of early-stage esophageal neoplasia are needed.
Aim: We sought to assess whether differential expression of microRNAs could discriminate between squamous epithelium, Barrett's esophagus (BE), and EAC.
Methods: We analyzed microRNA expression in a discovery cohort of human endoscopic biopsy samples from 36 patients representing normal squamous esophagus (n = 11), BE (n = 14), and high-grade dysplasia/EAC (n = 11). RNA was assessed using microarrays representing 847 human microRNAs followed by quantitative real-time polymerase chain reaction (qRT-PCR) verification of nine microRNAs. In a second cohort (n = 18), qRT-PCR validation of five miRNAs was performed. Expression of 59 microRNAs associated with BE/EAC in the literature was assessed in our training cohort. Known esophageal cell lines were used to compare miRNA expression to tissue miRNAs.
Results: After controlling for multiple comparisons, we found 34 miRNAs differentially expressed between squamous esophagus and BE/EAC by microarray analysis. However, miRNA expression did not reliably differentiate non-dysplastic BE from EAC. In the validation cohort, all five microRNAs selected for qRT-PCR validation differentiated between squamous samples and BE/EAC. Microarray results supported 14 of the previously reported microRNAs associated with BE/EAC in the literature. Cell lines did not generally reflect miRNA expression found in vivo.
Conclusions: These data indicate that miRNAs differ between squamous esophageal epithelium and BE/EAC, but do not distinguish between BE and EAC. We suggest prospective evaluation of miRNAs in patients at high risk for EAC.
ESOMIR: a curated database of biomarker genes and miRNAs associated with esophageal cancer.
Sindhoo A, Sipy S, Khan A, Selvaraj G, Alshammari A, Casida M Database (Oxford). 2023; 2023.
PMID: 37815872 PMC: 10563827. DOI: 10.1093/database/baad063.
Sugano K, Spechler S, El-Omar E, McColl K, Takubo K, Gotoda T Gut. 2022; 71(8):1488-1514.
PMID: 35725291 PMC: 9279854. DOI: 10.1136/gutjnl-2022-327281.
Computational pathology aids derivation of microRNA biomarker signals from Cytosponge samples.
Masque-Soler N, Gehrung M, Kosmidou C, Li X, Diwan I, Rafferty C EBioMedicine. 2022; 76:103814.
PMID: 35051729 PMC: 8883000. DOI: 10.1016/j.ebiom.2022.103814.
Lv J, Zhao H, Dai K, Cheng Y, Zhang J, Guo L World J Gastroenterol. 2020; 26(22):2889-2901.
PMID: 32587437 PMC: 7304109. DOI: 10.3748/wjg.v26.i22.2889.
Plasmonic nanobiosensors for detection of microRNA cancer biomarkers in clinical samples.
Crawford B, Wang H, Stolarchuk C, von Furstenberg R, Strobbia P, Zhang D Analyst. 2020; 145(13):4587-4594.
PMID: 32436503 PMC: 9532004. DOI: 10.1039/d0an00193g.